Agomelatine
Based on 9 publication(s) in Google Scholar
Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.55%
- No. CAS: 138112-76-2
- Fòrmula: C15H17NO2
- Peso molecular:243.30
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Oxygen Sensing Compound Library
HY-L045
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
Neurotransmitter Receptor Compound Library
HY-L062
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Alkaloids Library
HY-L071
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Targeted Diversity Library
HY-L099
-
Rare Diseases Drug Library
HY-L102
-
EMA-Approved Drug Library
HY-L116
-
5-HT Receptor Compound Library
HY-L121
-
Human Metabolite Library
HY-L123
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Chinese Baijiu Compound Library
HY-L241
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Agomelatine
More- Nat Commun. 2025 Nov 6;16(1):9812. [Abstract]
- NPJ Digit Med. 2025 Nov 17;8(1):663. [Abstract]
- Protein Cell. 2019 Mar;10(3):178-195. [Abstract]
- Cell Commun Signal. 2023 May 25;21(1):123. [Abstract]
- Neurosci Bull. 2025 Nov 18. [Abstract]
- Biochem Pharmacol. 2026 Feb:244:117624. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Pest Manag Sci. 2021 Jul;77(7):3561-3570. [Abstract]
- bioRxiv. 2025 Sep 21.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Flow Cytometry
-
Cell Migration/Invasion Assay
-
IF
-
WB
Ver todos los productos específicos de isoformas 5-HT Receptor
MoreVer todos los productos específicos de isoformas Endogenous Metabolite
More
Actividad biológica
|
5-HT2C Receptor |
5-HT2C Receptor 6.4 (pKi, native porcine) |
5-HT2C Receptor 6.2 (pKi, human) |
hMT1 0.1 nM (Ki, CHO Cells) |
hMT1 0.06 nM (Ki, HEK Cells) |
hMT2 0.12 nM (Ki, CHO Cells) |
hMT2 0.27 nM (Ki, HEK Cells) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
0.1 nM
Compound: 2
|
Agonist potency determined by [35S]GTP gamma-S binding assay using CHO cell lines for Melatonin receptor type 1B
Agonist potency determined by [35S]GTP gamma-S binding assay using CHO cell lines for Melatonin receptor type 1B
|
[PMID: 12646022] |
| CHO | EC50 |
0.18 nM
Compound: Agomelatin
|
Intrinsic activity at human MT2 receptor expressed in CHO cell membranes after 1 hr by [35S]GTPgammaS binding assay
Intrinsic activity at human MT2 receptor expressed in CHO cell membranes after 1 hr by [35S]GTPgammaS binding assay
|
[PMID: 26820449] |
| CHO | EC50 |
1.29 nM
Compound: 1
|
Agonist activity at human MT1 receptor expressed in CHO cells after 1 hr by [35S]GTPgammaS binding assay
Agonist activity at human MT1 receptor expressed in CHO cells after 1 hr by [35S]GTPgammaS binding assay
|
[PMID: 22301214] |
| CHO | EC50 |
1.4 nM
Compound: Agomelatin
|
Intrinsic activity at human MT1 receptor expressed in CHO cell membranes after 1 hr by [35S]GTPgammaS binding assay
Intrinsic activity at human MT1 receptor expressed in CHO cell membranes after 1 hr by [35S]GTPgammaS binding assay
|
[PMID: 26820449] |
| CHO | EC50 |
1.56 nM
Compound: 2
|
Agonist potency determined by [35S]GTP gamma-S binding assay using CHO cell lines for Melatonin receptor type 1A
Agonist potency determined by [35S]GTP gamma-S binding assay using CHO cell lines for Melatonin receptor type 1A
|
[PMID: 12646022] |
| CHO | EC50 |
1.6 nM
Compound: 1
|
Agonist activity at human MT1 receptor expressed in CHO cells by [35S]GTPgamma binding assay
Agonist activity at human MT1 receptor expressed in CHO cells by [35S]GTPgamma binding assay
|
[PMID: 20444610] |
Agomelatine (S 20098) acts as a full agonist of MT1 and MT2 receptors with EC50s of 1.6±0.4, 0.10±0.04 nM for CHO hMT1, CHO-hMT2 (hΜΤ1 and hΜΤ2 receptors expressed in CHO or HEK cell membranes)[1].
Agomelatine (S20098) also interacts with h5-HT2B receptors (6.6), whereas Agomelatine shows low affinity at native (rat)/cloned, human 5-HT2A (<5.0/5.3) and 5-HT1A (<5.0/5.2) receptors, and negligible (<5.0) affinity for other 5-HT receptors[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female Swiss mice (20-30 g) were administered PTZ (85 mg/kg, i.p.), PTX (7 mg/kg, i.p.), strychnine (75 mg/kg, i.p.), Pilocarpine (400 mg/kg, i.p.), respectively[3].
-
Dosage:25, 50, or 75 mg/kg
-
Administration:Administered intraperitoneally (i.p.)
-
Result:All dosages showed a significant decrease in thiobarbituric acid reactive substances (TBARS) levels and nitrite content in all brain areas when compared to controls in the Pilocarpine induced seizure model.
All dosages decreased TBARS levels in all brain areas, and at low doses (25 or 50 mg/kg) decreased nitrite contents, but only at 25 or 50 mg/kg showed a significant increase in catalase activity in three brain areas when compared to controls in the Strychnine-induced seizure model.
Did not have any antioxidant effects on parameters of oxidative stress produced by PTX- or PTZ-induced seizure models when compared to controls.
Chemical Information
-
No. CAS 138112-76-2
-
Appearance Solid
-
Peso molecular 243.30
-
Fòrmula C15H17NO2
-
Color White to off-white
-
SMILES
CC(NCCC1=C2C=C(OC)C=CC2=CC=C1)=O
-
Synonyms
S-20098
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2025 Nov 6;16(1):9812. PMID: 41198646 -
NPJ Digit Med
Tandospirone augments cisplatin treatment by lowering cholesterol and managing distress in NSCLC patients. [Abstract]2025 Nov 17;8(1):663. PMID: 41249389 -
Protein Cell
Identification of serotonin 2A receptor as a novel HCV entry factor by a chemical biology strategy. [Abstract]2019 Mar;10(3):178-195. PMID: 29542010 -
Cell Commun Signal
Tricyclic antidepressants induce liver inflammation by targeting NLRP3 inflammasome activation. [Abstract]2023 May 25;21(1):123. PMID: 37231437 -
Neurosci Bull
Agomelatine Targets Aquaporin-4 Polarization to Rescue Glymphatic Dysfunction in Parkinson's Disease. [Abstract]2025 Nov 18. PMID: 41251938 -
Biochem Pharmacol
Agomelatine alleviates hypoxia-induced pulmonary arterial hypertension by activating mitophagy via the SIRT1/FoxO1/ULK1 signaling pathway. [Abstract]2026 Feb:244:117624. PMID: 41360230
Agomelatine purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2026 Feb:244:117624. [Abstract]
PASMCs exposed to Agomelatine (AGM) (0.1–100 μM) for 48 h under normoxia with viability quantified by CCK-8 assay.
Agomelatine purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2026 Feb:244:117624. [Abstract]
Cell cycle analysis by flow cytometry of control, hypoxia and hypoxia + Agomelatine (AGM) (10 μM) groups.
Agomelatine purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2026 Feb:244:117624. [Abstract]
Cell migration determined by transwell migration assay treated with Agomelatine (AMG) (10 μM).
Agomelatine purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2026 Feb:244:117624. [Abstract]
Representative photographs of the EdU incorporation assay of PASMCs treated with Agomelatine (AMG) (10 μM).
Agomelatine purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2026 Feb:244:117624. [Abstract]
Western blot analysis of PCNA in control, hypoxia and hypoxia + Agomelatine (AGM) (10 μM) groups.
-
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Pest Manag Sci
MicroRNA-315-5p promotes rice black-streaked dwarf virus infection by targeting a melatonin receptor in the small brown planthopper. [Abstract]2021 Jul;77(7):3561-3570. PMID: 33840148 -
Solvente y solubilidad
DMSO : ≥ 100 mg/mL (411.02 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.28 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.28 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (399 KB)
- English - EN (399 KB)
- Français - FR (399 KB)
- Deutsch - DE (399 KB)
- Norwegian - NO (399 KB)
- Español - ES (399 KB)
- Swedish - SV (399 KB)
- Italian - IT (399 KB)
- Portuguese - PT (399 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Audinot V, et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61. [Content Brief]
[2]. Millan MJ, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003 Sep;306(3):954-64. [Content Brief]
[3]. Aguiar CC, et al. Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures. Cell Mol Neurobiol. 2013 Aug;33(6):825-35. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.1102 mL | 20.5508 mL | 41.1015 mL | 102.7538 mL |
| 5 mM | 0.8220 mL | 4.1102 mL | 8.2203 mL | 20.5508 mL | |
| 10 mM | 0.4110 mL | 2.0551 mL | 4.1102 mL | 10.2754 mL | |
| 15 mM | 0.2740 mL | 1.3701 mL | 2.7401 mL | 6.8503 mL | |
| 20 mM | 0.2055 mL | 1.0275 mL | 2.0551 mL | 5.1377 mL | |
| 25 mM | 0.1644 mL | 0.8220 mL | 1.6441 mL | 4.1102 mL | |
| 30 mM | 0.1370 mL | 0.6850 mL | 1.3701 mL | 3.4251 mL | |
| 40 mM | 0.1028 mL | 0.5138 mL | 1.0275 mL | 2.5688 mL | |
| 50 mM | 0.0822 mL | 0.4110 mL | 0.8220 mL | 2.0551 mL | |
| 60 mM | 0.0685 mL | 0.3425 mL | 0.6850 mL | 1.7126 mL | |
| 80 mM | 0.0514 mL | 0.2569 mL | 0.5138 mL | 1.2844 mL | |
| 100 mM | 0.0411 mL | 0.2055 mL | 0.4110 mL | 1.0275 mL |
Powered by Bioz